S. Montgomery

发表

A New Depression Scale Designed to be Sensitive to Change

M. Åsberg, S. Montgomery, 1979, British Journal of Psychiatry.

Anxiety and Depression

S. Montgomery, 1990 .

5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder

P. Verbanck, Y. Lecrubier, S. Kasper, 2010, International clinical psychopharmacology.

The antidepressant efficacy of citalopram

S. Montgomery, L. Djärv, 1996, International clinical psychopharmacology.

Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study.

Julien Mendlewicz, Siegfried Kasper, Koen Demyttenaere, 2007, The Journal of clinical psychiatry.

AMITRIPTYLINE PLASMA-CONCENTRATION AND CLINICAL EFFECT A World Health Organisation Collaborative Study

S. Montgomery, A. Coppen, F. van de Poel, 1978, The Lancet.

Cardiovascular effects of amitriptyline, mianserin, zimelidine and nomifensine in depressed patients.

S. Montgomery, C. Burgess, P. Turner, 1979, Postgraduate medical journal.

Pharmacokinetics and efficacy of maprotiline and amitriptyline in endogenous depression: a double-blind controlled trial.

R. Braithwaite, S. Montgomery, S. Dawling, 1980, Clinical therapeutics.

Selective serotonin reuptake inhibitors

D. Nutt, I. Hindmarch, T. Dinan, 1994 .

Pregabalin for the treatment of generalised anxiety disorder

S. Montgomery, 2006, Expert opinion on pharmacotherapy.

Rapid onset of action of venlafaxine

S. Montgomery, 1995, International clinical psychopharmacology.

Evaluation of depressive symptoms in patients with coronary artery disease using the Montgomery Åsberg Depression Rating Scale

S. Montgomery, V. Pop, A. Bunevičius, 2012, International clinical psychopharmacology.

Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey

R. Kessler, H. Wittchen, S. Montgomery, 2000, International clinical psychopharmacology.

Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders.

S. Montgomery, 2002, International clinical psychopharmacology.

WCA Recommendations for the Long-Term Treatment of Obsessive-Compulsive Disorder in Adults

E. Hollander, D. Nutt, J. Greist, 2003, CNS Spectrums.

Phenomenology and Differential Diagnostic Status of Obsessive-Compulsive Disorder

N. Fineberg, S. Montgomery, D. Montgomery, 1992 .

Is long-term treatment effective in OCD?

N. Fineberg, S. Montgomery, R. Evans, 1993, European Neuropsychopharmacology.

Psychopharmacology of Obsessive-Compulsive Disorder

S. Montgomery, 1998, CNS Spectrums.

Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control

S. Kasper, E. Corruble, A. Hale, 2013, International clinical psychopharmacology.

Treatment of Obsessive-Compulsive Disorder

S. Montgomery, 1999, CNS Spectrums.

Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model.

M. Papp, S. Montgomery, C. Sánchez, 2001, Pharmacology & toxicology.

Routine nortriptyline levels in treatment of depression.

R. Braithwaite, S. Montgomery, J. Crammer, 1977, British medical journal.

Tolerability of Serotonin Norepinephrine Reuptake Inhibitor Antidepressants

S. Montgomery, 2008, CNS Spectrums.

Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR.

D. Sheehan, S. Montgomery, V. Haudiquet, 2002, Journal of psychiatric research.

The Evidence for 20 mg a day of Fluoxetine as the Optimal Dose in the Treatment of Depression

A. Altamura, S. Montgomery, J. Wernicke, 1988, British Journal of Psychiatry.

The Influence of Different Relapse Criteria on the Assessment of Long‐Term Efficacy of Sertraline

S. Montgomery, R. Burnside, D. Doogan, 1991, International clinical psychopharmacology.

The need for long term treatment of depression

S. Montgomery, 1997, European Neuropsychopharmacology.

Selective serotonin reuptake inhibitors: Therapeutic alternatives to the tricyclics in the treatment of major depression

D. Dunner, S. Montgomery, 1995 .

Suicide and Antidepressants

S. Montgomery, Stuart A Montgomery, 2012, Drugs.

Antidepressant Therapy at the Dawn of the Third Millennium

S. Montgomery, M. Briley, 1999 .

Predicting response: noradrenaline reuptake inhibition.

S. Montgomery, 1999, International clinical psychopharmacology.

Letter: Tryptophan in depression.

S. Montgomery, A. Coppen, 1974, Lancet.

Long‐term management of obsessive‐compulsive disorder

S. Montgomery, 1996, International clinical psychopharmacology.

Early response with clomipramine in obsessive compulsive disorder — A placebo controlled study

N. Fineberg, S. Montgomery, D. Montgomery, 1990, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

The optimal dosing regimen for citalopram‐a meta‐analysis of nine placebo‐controlled studies

S. Montgomery, P. Rioux, P. Tanghøj, 1994, International clinical psychopharmacology.

PLASMA AMITRIPTYLINE AND CLINICAL EFFECT

S. Montgomery, A. Coppen, A. Darragh, 1978, The Lancet.

Side effects, dropouts from treatment and cost consequences

S. Kasper, S. Montgomery, 1998, International clinical psychopharmacology.

Antidepressants in the prophylactic treatment of recurrent major depression

S. Montgomery, A. Roberts, 1994 .

Antidepressants in long-term treatment.

S. Montgomery, Stuart A. Montgomery, M.D, 1994, Annual review of medicine.

Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment.

S Kasper, M Lader, M. Stein, 2000, Journal of affective disorders.

Social phobia: long‐term treatment outcome and prediction of response - a moclobemide study

S. Montgomery, M. Versiani, R. Amrein, 1997, International clinical psychopharmacology.

Antidepressant efficacy in relation to item analysis and severity of depression: a placebo‐controlled trial of fluvoxamine versus imipramine

H. Möller, S. Kasper, S. Montgomery, 1995, International clinical psychopharmacology.

Variation in the HTR1A and HTR2A genes and social adjustment in depressed patients.

A. Serretti, S. Kasper, J. Mendlewicz, 2013, Journal of affective disorders.

Efficacy and tolerability of milnacipran: an overview

S. Montgomery, M. Briley, A. Solles, 1996, International clinical psychopharmacology.

A 24‐week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression

S. Montgomery, P. Tanghøj, J. Rasmussen, 1993, International clinical psychopharmacology.

Efficacy, safety, and indications for tricyclic and newer antidepressants

A. Rush, J. Lépine, S. Kasper, 1994 .

The advantages of paroxetine in different subgroups of depression.

S. Montgomery, Stuart A. Montgomery, 1992, International clinical psychopharmacology.

The duration, nature and recurrence rate of brief depressions

S. Montgomery, D. Baldwin, Mary Green, 1990, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

The place of reboxetine in antidepressant therapy

S. Montgomery, 1998 .

S-38-1 Treatment of social phobia

S. Montgomery, D. Montgomery, A. Kotak, 1996, European Neuropsychopharmacology.

Depression: a long‐term illness and its treatment

S. Kasper, S. Montgomery, S. Kasper, 1998, International clinical psychopharmacology.

Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability

S. Montgomery, B. Emir, R. Prieto, 2013, Current medical research and opinion.

Psychotic Features in Patients With Major Depressive Disorder: A Report From the European Group for the Study of Resistant Depression.

A. Serretti, L. Bartova, S. Kasper, 2019, The Journal of clinical psychiatry.

Venlafaxine: a new dimension in antidepressant pharmacotherapy.

J. Feighner, S. Montgomery, A. Frazer, 1993, The Journal of clinical psychiatry.

Neuroendocrine responses to intravenous L-tryptophan in obsessive compulsive disorder.

P. Cowen, N. Fineberg, S. Montgomery, 1994, Journal of affective disorders.

SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OCD

N. Fineberg, S. Montgomery, D. Montgomery, 1992, Clinical neuropharmacology.

Treatment of depression with associated anxiety: comparisons of tricyclic antidepressants and selective serotonin reuptake inhibitors

S. Montgomery, S. Montgomery, R. Judge, 2000, Acta psychiatrica Scandinavica. Supplementum.

New developments in the treatment of depression.

S. Montgomery, Stuart A. Montgomery, 1999, The Journal of clinical psychiatry.

A Double-Blind Comparison of Lithium Carbonate and Maprotiline in the Prophylaxis of the Affective Disorders

S. Montgomery, A. Coppen, R. Gupta, 1976, British Journal of Psychiatry.

A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder

S. Montgomery, E. Vieta, A. Schreiner, 2012, European Neuropsychopharmacology.

The Benefits and Risks of 5-HT Uptake Inhibitors in Depression: Chairman's Introduction

S. Montgomery, 1988, British Journal of Psychiatry.

Is there a Relationship between Serotonin Receptor Subtypes and Selectivity of Response in Specific Psychiatric Illnesses?

N. Fineberg, S. Montgomery, 1989, British Journal of Psychiatry.

Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression

D. Rujescu, C. Lewis, A. Serretti, 2020, medRxiv.

Treatment-resistant Depression: Kasper/Treatment-resistant Depression

S. Kasper, S. Montgomery, 2013 .

PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway

A. Serretti, S. Kasper, J. Mendlewicz, 2014, The Pharmacogenomics Journal.

Pharmacological differences between brief and major depressions

S. Montgomery, R. Evans, D. Montgomery, 1993, European Neuropsychopharmacology.

Noradrenergic symptom cluster in depression

S. Montgomery, M. Briley, 2011, Neuropsychiatric disease and treatment.

Measurement of change in psychiatric illness: new obsessional, schizophrenia and depression scales.

S. Montgomery, D. Montgomery, 1980, Postgraduate medical journal.

Development of a schizophrenia scale sensitive to change

S. Montgomery, D. Montgomery, P. Taylor, 1978, Neuropharmacology.

Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder

S. Montgomery, C. François, Jose-Luis Fernandez, 2012, PharmacoEconomics.

Social functioning in depression: a review.

M B Keller, S Kasper, H. Möller, 2000, The Journal of clinical psychiatry.

Prophylaxis in recurrent unipolar depression: a new indication for treatment studies

S. Montgomery, 1989, Journal of psychopharmacology.

The Prophylactic Efficacy of Fluoxetine in Unipolar Depression

S. Montgomery, J. Danion, J. Beuzen, 1988, British Journal of Psychiatry.

Continuation Therapy with Amitriptyline in Depression

S. Montgomery, A. Coppen, K. Ghose, 1978, British Journal of Psychiatry.

Long-Term Treatment of Depression

S. Montgomery, 1994, British Journal of Psychiatry.

Relapse prevention with antidepressants

S. Montgomery, R. Evans, 1993 .

Features of recurrent brief depression.

S. Montgomery, D. Montgomery, 1992, L'Encephale.

The prevention of recurrent suicidal acts.

S. Montgomery, D. Montgomery, D. Roy, 1983, British journal of clinical pharmacology.

Switching Antidepressant Class Does Not Improve Response or Remission in Treatment-Resistant Depression

A. Serretti, Y. Lecrubier, S. Kasper, 2011, Journal of clinical psychopharmacology.

A double blind comparison of lithium carbonate and ludiomil in the prophylaxis of unipolar affective illness.

S. Montgomery, A. Coppen, J. Bailey, 1976, Pharmakopsychiatrie, Neuro-Psychopharmakologie.

Guidelines for treating depressive illness with antidepressants

C. Katona, B. Leonard, P. Bebbington, 1993, Journal of psychopharmacology.

A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine

S. Montgomery, R. Nielsen, L. Poulsen, 2014, Human psychopharmacology.

A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?

S. Montgomery, C. Sánchez, E. Reines, 2014, International clinical psychopharmacology.

Pharmacological prevention of suicidal behaviour.

S. Montgomery, D. Montgomery, 1982, Journal of affective disorders.

Efficacy in long-term treatment of depression.

S. Montgomery, 1996, The Journal of clinical psychiatry.

Antidepressants and seizures: emphasis on newer agents and clinical implications

S. Montgomery, 2005, International journal of clinical practice.

295 – A double blind comparison of antidepressant efficacy of zimelidine, a new 5 HT uptake inhibitor with amitriptyline

S. Montgomery, R. McAuley, D. Montgomery, 1978 .

Prevalence of anxiety disorders comorbidity in bipolar depression, unipolar depression and dysthymia.

S. Montgomery, G. Cassano, S. Pini, 1997, Journal of affective disorders.

Plasma levels and clinical response with imipramine in a study comparing efficacy with mianserin and nomifensine.

S. Montgomery, D. Montgomery, D. Roy, 1983, British journal of clinical pharmacology.

Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine.

S. Kasper, S. Montgomery, G. Zornberg, 2006, The Journal of clinical psychiatry.

Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder

S. Montgomery, K. Chatamra, E. Whalen, 2008, British Journal of Psychiatry.

Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder

D. Rujescu, A. Serretti, S. Kasper, 2020, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Chairman's overview. The place of reboxetine in antidepressant therapy.

S. Montgomery, 1998, The Journal of clinical psychiatry.

The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study

A. Serretti, S. Kasper, J. Mendlewicz, 2017, The international journal of neuropsychopharmacology.

Association study of CREB1 polymorphisms and suicidality in MDD: results from a European multicenter study on treatment resistant depression

A. Serretti, S. Kasper, J. Mendlewicz, 2015, The International journal of neuroscience.

The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk—a European multicentre study on treatment-resistant major depressive disorder

A. Serretti, S. Kasper, J. Mendlewicz, 2013, European Archives of Psychiatry and Clinical Neuroscience.

Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment

C. Lewis, A. Serretti, S. Montgomery, 2020, International clinical psychopharmacology.

Lithium, Thyroid Hormones and Further Augmentation Strategies in Treatment‐resistant Depression

S. Kasper, M. Bauer, S. Montgomery, 2013 .

Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder

Dan J Stein, D. Stein, S. Kasper, 2001, International clinical psychopharmacology.

Bipolar II disorder as a risk factor for postpartum depression.

A. Serretti, L. Mandelli, L. Bartova, 2016, Journal of affective disorders.

Economic Analysis of Treating Depression with Nefazodone v. Imipramine

S. Montgomery, M. Clark, R. Brown, 1996, British Journal of Psychiatry.

The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives

D. Rujescu, A. Serretti, S. Kasper, 2018, The international journal of neuropsychopharmacology.

Why do we need new and better antidepressants?

S. Montgomery, 2006, International clinical psychopharmacology.

Evidence-based prescribing of antidepressants

S. Montgomery, 2003, International journal of psychiatry in clinical practice.

Late-Life Depression: Rationalizing Pharmacological Treatment Options

S. Montgomery, 2002, Gerontology.

Pharmacotherapy of depression and mixed states in bipolar disorder.

J. Guelfi, C. Nemeroff, A. Schatzberg, 2000, Journal of affective disorders.

Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine

S. Kasper, S. Montgomery, 2007, International clinical psychopharmacology.

Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder

Dan J Stein, D. Stein, S. Kasper, 2001, International clinical psychopharmacology.

A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group.

A. McIntyre, J. Zohar, S. Montgomery, 1993, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology.

Selective serotonin reuptake inhibitors: meta‐analysis of discontinuation rates

D. Nutt, I. Hindmarch, T. Dinan, 1994, International clinical psychopharmacology.

First clinical experience with olanzapine (LY 170053): results of an open‐label safety and dose‐ranging study in patients with schizophrenia

S. Montgomery, D. Baldwin, 1995, International clinical psychopharmacology.

Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD)

A. Serretti, L. Bartova, S. Kasper, 2018, The international journal of neuropsychopharmacology.

Partial response and nonresponse to antidepressant therapy: current approaches and treatment options.

Riccardo Torta, Julien Mendlewicz, Hans-Jürgen Möller, 2002, The Journal of clinical psychiatry.

Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta‐analysis

S. Kasper, S. Montgomery, S. Kasper, 1995, International clinical psychopharmacology.

Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction.

S. Montgomery, D. Baldwin, A. Riley, 2002, Journal of affective disorders.

First International Exchange on Bipolar Disorder.

P. Keck, S. Montgomery, 2000, Journal of affective disorders.

Treatment resistance in severe unipolar depression: no association with psychotic or melancholic features.

A. Serretti, S. Kasper, J. Mendlewicz, 2013, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder

Dan J Stein, E. Hollander, D. Nutt, 2003, CNS Spectrums.

A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping

D. Rujescu, C. Lewis, A. Serretti, 2019, Translational Psychiatry.

Results of the European Group for the Study of Resistant Depression (GSRD) — basis for further research and clinical practice

A. Serretti, L. Bartova, S. Kasper, 2019, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance

A. Serretti, S. Kasper, J. Mendlewicz, 2017, European Archives of Psychiatry and Clinical Neuroscience.

Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples

D. Rujescu, C. Lewis, A. Serretti, 2018, British Journal of Psychiatry.

Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study.

A. Serretti, S. Kasper, J. Mendlewicz, 2016, Journal of affective disorders.

Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease

L. Thal, S. Montgomery, R. Amrein, 2003, International clinical psychopharmacology.

Desvenlafaxine for the Prevention of Relapse in Major Depressive Disorder: Results of a Randomized Trial

J. Guelfi, S. Montgomery, K. Rickels, 2010, Journal of clinical psychopharmacology.

Venlafaxine versus placebo in the preventive treatment of recurrent major depression.

S. Montgomery, R. Entsuah, D. Hackett, 2004, The Journal of clinical psychiatry.

Fluvoxamine prevents recurrence of depression: results of a long‐term, double‐blind, placebo‐controlled study

S. Montgomery, J. Terra, 1998, International clinical psychopharmacology.

Citalopram in doses of 20–60 mg is effective in depression relapse prevention: a placebo‐controlled 6 month study

J. Lépine, H. Lôo, S. Montgomery, 1995, International clinical psychopharmacology.

Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression

G. Dunbar, S. Montgomery, Montgomery Sa, 1993, International clinical psychopharmacology.

Amitriptyline plasma concentration and clinical response.

R. Braithwaite, S. Montgomery, S. Dawling, 1979, British medical journal.

Critical issues in the treatment of affective disorders

D. Kupfer, C. Nemeroff, L. Judd, 1995 .

Discontinuation symptoms in depression and anxiety disorders.

S. Montgomery, D. Baldwin, M. Lader, 2007, The international journal of neuropsychopharmacology.

Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder

M. Fava, S. Montgomery, S. K. Padmanabhan, 2009, International clinical psychopharmacology.

Serotonin noradrenaline reuptake inhibitors: Logical evolution of antidepressant development

S. Montgomery, 2006, International journal of psychiatry in clinical practice.

A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder.

S. Montgomery, J. Boulenger, H. Loft, 2005, The Journal of clinical psychiatry.

Antidepressants and heart disease

S. Montgomery, R. Farmer, 1984 .

Prediction of plasma levels and clinical response in depression

S. Montgomery, 1981 .

Maprotiline, nomifensine, mianserin, zimelidine: A review of antidepressant efficacy in in-patients

S. Montgomery, 1980, Neuropharmacology.

Measurement of serum drug levels in the assessment of antidepressants.

S. Montgomery, Stuart A. Montgomery, 1980, British journal of clinical pharmacology.

Profile of antidepressant action of zimelidine and norzimelidine compared with amitriptyline.

S. Montgomery, R. McAuley, D. Montgomery, 1982, Advances in biochemical psychopharmacology.

Neuronal cell adhesion genes and antidepressant response in three independent samples

A. Serretti, D. Gurwitz, S. Kasper, 2015, The Pharmacogenomics Journal.

Suicide and Antidepressants

S. Montgomery, 2012, Drugs.

What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram

A. Serretti, S. Kasper, G. Papadimitriou, 2015, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Escitalopram versus venlafaxine XR in the treatment of depression

S. Montgomery, H. Andersen, 2006, International clinical psychopharmacology.

Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study.

S. Montgomery, M. Brecher, A. Lazarus, 2009, The Journal of clinical psychiatry.

The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression

Pia Baldinger, Rupert Lanzenberger, Julien Mendlewicz, 2015, European Neuropsychopharmacology.

Is there a role for a pure noradrenergic drug in the treatment of depression?

S. Montgomery, 1997, European Neuropsychopharmacology.

Reboxetine: additional benefits to the depressed patient.

S. Montgomery, 1997, Journal of psychopharmacology.

Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial

S. Montgomery, U. Lepola, P. Boyer, 2008, International clinical psychopharmacology.

Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression.

A. Serretti, S. Kasper, J. Mendlewicz, 2018, Journal of affective disorders.

Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials

S. Montgomery, C. Gommoll, Changzheng Chen, 2014, CNS Spectrums.

Social adjustment among treatment responder patients with mood disorders.

A. Serretti, S. Kasper, J. Mendlewicz, 2013, Journal of affective disorders.

Major depressive disorders: clinical efficacy and tolerability of agomelatine, a new melatonergic agonist

S. Montgomery, 2006, European Neuropsychopharmacology.

Guidelines in major depressive disorder, and their limitations

S. Montgomery, 2006, International journal of psychiatry in clinical practice.

Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression

A. Serretti, L. Bartova, S. Kasper, 2020, The international journal of neuropsychopharmacology.

Diarrhoea during treatment with clozapine: association with lymphocyte count.

R. Harvey, S. Montgomery, T. Bullock, 1992, BMJ.

The Role of Atypical Antipsychotics in Inadequate‐response and Treatment‐resistant Depression

S. Kasper, S. Montgomery, E. Akimova, 2013 .

The psychopharmacology of borderline personality disorders.

S. Montgomery, 1987, Acta psychiatrica Belgica.

Treatment‐resistant Depression

H. Möller, S. Kasper, S. Montgomery, 2013 .

Mianserin in the Prophylaxis of Suicidal Behaviour: a Double Blind Placebo Controlled Trial

S. Montgomery, D. Roy, D. Montgomery, 1983 .

Low comorbid obsessive-compulsive disorder in patients with major depressive disorder - Findings from a European multicenter study.

A. Serretti, L. Bartova, S. Kasper, 2018, Journal of affective disorders.

Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study.

A. Serretti, L. Bartova, S. Kasper, 2017, Journal of psychiatric research.

Early improvement with pregabalin predicts endpoint response in patients with generalized anxiety disorder: an integrated and predictive data analysis

M. Almas, S. Montgomery, E. Whalen, 2017, International clinical psychopharmacology.

The impact of serotonin receptor 1A and 2A gene polymorphisms and interactions on suicide attempt and suicide risk in depressed patients with insufficient response to treatment – a European multicentre study

A. Serretti, S. Kasper, J. Mendlewicz, 2016, International clinical psychopharmacology.

Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability

S. Montgomery, A. Puech, M. Briley, 1997, International clinical psychopharmacology.

Citalopram versus desipramine in treatment resistant depression: Effect of continuation or switching strategies. A randomized open study

A. Serretti, S. Kasper, J. Mendlewicz, 2011, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Refining Prediction in Treatment-Resistant Depression: Results of Machine Learning Analyses in the TRD III Sample.

Rupert Lanzenberger, Julien Mendlewicz, Thomas Vanicek, 2017, The Journal of clinical psychiatry.

A New Prediction Model for Evaluating Treatment-Resistant Depression.

Rupert Lanzenberger, Julien Mendlewicz, Thomas Vanicek, 2017, The Journal of clinical psychiatry.

Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder.

S. Kasper, M. Bauer, S. Montgomery, 2013, Journal of affective disorders.

WCA Recommendations for the Long-Term Treatment of Social Phobia

Dan J Stein, E. Hollander, D. Nutt, 2003, CNS Spectrums.

Thyrotrophin-releasing hormone in the treatment of depression.

S. Montgomery, A. Coppen, V. Marks, 1974, Lancet.

Influence of family history of major depression, bipolar disorder, and suicide on clinical features in patients with major depression and bipolar disorder

A. Serretti, S. Kasper, J. Mendlewicz, 2013, European Archives of Psychiatry and Clinical Neuroscience.

Efficacy of once-daily extended release quetiapine fumarate in patients with different levels of severity of generalized anxiety disorder

S. Montgomery, H. Svedsäter, H. Eriksson, 2014, International clinical psychopharmacology.

Pharmacotherapy Update: Pregabalin in the Treatment of Generalized Anxiety Disorder

S. Kasper, S. Montgomery, 2010 .

The efficacy of pregabalin and benzodiazepines in generalized anxiety disorder presenting with high levels of insomnia

S. Montgomery, B. Herman, E. Schweizer, 2009, International clinical psychopharmacology.

Pregabalin for the treatment of generalized anxiety disorder (GAD): Efficacy and safety in elderly patients

S. Montgomery, K. Chatamra, F. Mandel, 2007, European psychiatry.

Milnacipran: recent findings in depression

S. Montgomery, M. Briley, 2010, Neuropsychiatric Disease and Treatment.

THE USE OF THE MADRS IN MEASURING PROFILES OF ACTION

S. Montgomery, C. Robinson, D. Goold, 1984 .

A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression

S. Montgomery, Stuart A. Montgomery, 2001, International clinical psychopharmacology.

Implications of the severity of social phobia.

S. Montgomery, 1998, Journal of affective disorders.

The serotonin transporter and the activity regulated cytoskeleton‐associated protein genes in antidepressant response and resistance: 5‐HTTLPR and other variants

A. Serretti, S. Kasper, J. Mendlewicz, 2018, Human psychopharmacology.

Mirtazapine versus amitriptyline in the long‐term treatment of depression: a double‐blind placebo‐controlled study

S. Montgomery, P. Reimitz, M. Zivkov, 1998, International Clinical Psychopharmacology.

Which antidepressants have demonstrated superior efficacy? A review of the evidence

Naomi A. Fineberg, Hans-Jürgen Möller, Siegfried Kasper, 2007, International clinical psychopharmacology.

Serotonin, sertraline and depression

S. Montgomery, 1995, Journal of psychopharmacology.

Duloxetine in the prevention of relapse of major depressive disorder

M. Detke, S. Montgomery, A. Montejo, 2006, British Journal of Psychiatry.

Efficacy and safety of the selective serotonin reuptake inhibitors in treating depression in elderly patients

S. Montgomery, 1998, International clinical psychopharmacology.

Brain 5-HT function in obsessive-compulsive disorder

P. Cowen, N. Fineberg, S. Montgomery, 1997, British Journal of Psychiatry.

Prediction of Steady‐State Plasma Concentrations and Individual Dosage Regimens of Tricyclic Antidepressants from a Single Test Dose

R. Braithwaite, S. Montgomery, S. Dawling, 1982, Therapeutic drug monitoring.

Lack of Efficacy of the Substance P (Neurokinin1 Receptor) Antagonist Aprepitant in the Treatment of Major Depressive Disorder

Jarmo Hietala, Mary Morrison, Duane Snavely, 2006, Biological Psychiatry.

Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study

D. Rujescu, G. Kranz, A. Serretti, 2018, Acta psychiatrica Scandinavica.

Selecting methodologies for the evaluation of differences in time to response between antidepressants.

H. Möller, A. Nierenberg, M. Thase, 2002, The Journal of clinical psychiatry.

Ssris and Deliberate Self-harm Ssris and Deliberate Self-harm

D. Healy, W. Brown, S. Montgomery, 2022 .

Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder

P. Auquier, S. Montgomery, S. Aballéa, 2008, International journal of clinical practice.

A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder

S. Montgomery, Krishnan Padmanabhan, B. Pitrosky, 2008, International clinical psychopharmacology.

Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients

S. Curry, S. Montgomery, D. Wiles, 2004, Psychopharmacology.

Fluvoxamine in the treatment of obsessive compulsive disorder

S. Montgomery, A. Manceaux, 1992, International clinical psychopharmacology.

SSRIs in depression and anxiety

J. A. Boer, S. Montgomery, 2001 .

Clinical correlates of augmentation/combination treatment strategies in major depressive disorder

A. Serretti, L. Bartova, S. Kasper, 2018, Acta psychiatrica Scandinavica.

Definitions and Predictors of Treatment‐resistant Depression

S. Kasper, D. Souery, S. Montgomery, 2013 .

Dosage Adjustment from Simple Nortriptyline Spot Level Predictor Tests in Depressed Patients

R. Braithwaite, S. Montgomery, S. Dawling, 1979, Clinical pharmacokinetics.

Nortriptyline in depressed patients with high plasma levels. II

R. Braithwaite, S. Montgomery, Sheila Dawling, 1978, Clinical pharmacology and therapeutics.

Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder

D. Stein, S. Montgomery, R. Amrein, 2002, International clinical psychopharmacology.

Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder.

M. Fava, S. Montgomery, S. Durgam, 2016, The Journal of clinical psychiatry.

Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies

S. Montgomery, A. Lazarus, R. Weisler, 2012, International clinical psychopharmacology.

Opinion paper: poor response to treatment of depression in people in high occupational levels

A. Serretti, L. Mandelli, S. Kasper, 2018, Psychological Medicine.

Theoretical and practical implications of a controlled trial of an alpha 2-adrenoceptor antagonist in the treatment of depression.

S. Montgomery, 1989, Psychopharmacology series.

Improving the chance of recovery from the short‐ and long‐term consequences of depression

H. Möller, K. Demyttenaere, S. Montgomery, 2003, International clinical psychopharmacology.

Family history of major depression and residual symptoms in responder and non-responder depressed patients.

A. Serretti, S. Kasper, J. Mendlewicz, 2014, Comprehensive psychiatry.

Plasma concentration of clomipramine and desmethylclomipramine and clinical response in depressed patients.

R. Braithwaite, S. Montgomery, S. Dawling, 1980, Postgraduate medical journal.

Temperament and character influence on depression treatment outcome.

D. Rujescu, A. Serretti, S. Kasper, 2019, Journal of affective disorders.

L-101 Acute and long term treatment — How long do you need to treat depression?

S. Montgomery, 1996, European Neuropsychopharmacology.

Treatment of Affective Disorders

S. Montgomery, 1996 .

Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder

Y. Lecrubier, S. Kasper, J. Mendlewicz, 2011, International clinical psychopharmacology.

Psychopharmacology of panic

S. Montgomery, 1993 .

Lack of efficacy of moclobemide or imipramine in the treatment of recurrent brief depression: results from an exploratory randomized, double-blind, placebo-controlled treatment study

S. Montgomery, D. Baldwin, M. Green, 2014, International clinical psychopharmacology.

Temperament and character profiles in bipolar I, bipolar II and major depressive disorder: Impact over illness course, comorbidity pattern and psychopathological features of depression.

A. Serretti, S. Kasper, J. Mendlewicz, 2015, Journal of affective disorders.

The Antidepressant Efficacy of Reboxetine in Patients with Severe Depression

S. Montgomery, J. Ferguson, G. Schwartz, 2003, Journal of clinical psychopharmacology.

Humanistic and economic burden of generalized anxiety disorder in North America and Europe.

D. Sheehan, D. Revicki, K. Wyrwich, 2012, Journal of affective disorders.

The under-recognized role of dopamine in the treatment of major depressive disorder.

S. Montgomery, 2008, International clinical psychopharmacology.

Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder

H. Möller, S. Kasper, S. Montgomery, 2010, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levels

A. Altamura, S. Montgomery, H. Eriksson, 2014, International clinical psychopharmacology.

Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.

S. Montgomery, L. Mansuy, Dayong Li, 2013, The Journal of clinical psychiatry.

Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?

H. Möller, S. Montgomery, 2009, International clinical psychopharmacology.

Efficacy and safety of 30 mg/d and 45 mg/d nemifitide compared to placebo in major depressive disorder.

J. Feighner, R. Shrivastava, S. Montgomery, 2006, The international journal of neuropsychopharmacology.

Eﬃcacy and safety of 30 mg/d and 45 mg/d nemiﬁtide compared to placebo in major depressive disorder

J. Feighner, R. Shrivastava, S. Montgomery, 2006 .

Acute hypertensive episode induced by sulpiride – a case report

S. Montgomery, R. Mayer, 1989 .

Genetics of Treatment‐resistant Depression

A. Serretti, S. Kasper, S. Montgomery, 2013 .

Pooled analysis of sustained response rates for extended release quetiapine fumarate as monotherapy or adjunct to antidepressant therapy in patients with major depressive disorder.

R. McIntyre, M. Bauer, S. Montgomery, 2013, Journal of affective disorders.

Identification of clinical factors associated with resistance to antidepressants in bipolar depression: results from an European Multicentre Study

A. Serretti, Y. Lecrubier, S. Kasper, 2010, International clinical psychopharmacology.

Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study

S. Montgomery, Gang Wang, G. Filippov, 2015, Current medical research and opinion.

Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy

M. Trivedi, M. Thase, M. Bauer, 2013, International clinical psychopharmacology.

Comparative efficacy of antidepressants. Discussion

H. Möller, Y. Lecrubier, S. Kasper, 1992 .

Dysbindin gene (DTNBP1) in major depressive disorder (MDD) patients: Lack of association with clinical phenotypes

Y. Lecrubier, S. Kasper, J. Mendlewicz, 2010, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study

S. Montgomery, C. Gommoll, L. Mansuy, 2013, International clinical psychopharmacology.

Selective Serotonin Reuptake Inhibitors in Older Patients

S. Montgomery, R. Evans, U. Skerritt, 1997, Drugs & aging.

Moclobemide in the treatment of social phobia.

D. Nutt, S. Montgomery, 1996 .

The efficacy of fluoxetine as an antidepressant in the short and long term.

S. Montgomery, 1989, International clinical psychopharmacology.

Fluoxetine compared with amitriptyline in elderly depression: a controlled clinical trial.

A. Altamura, S. Montgomery, G. Invernizzi, 1989, International journal of clinical pharmacology research.

Efficacy of escitalopram compared to citalopram: a meta-analysis.

S. Kasper, S. Montgomery, T. Hansen, 2011, The international journal of neuropsychopharmacology.

The Role of Psychotherapy in the Management of Treatment‐resistant Depression

M. Thase, S. Kasper, S. Montgomery, 2013 .

The specificity of the zimelidine reaction.

S. Montgomery, P. Burkitt, R. Gabriel, 1989, International clinical psychopharmacology.

Attrition in treatment-resistant depression: predictors and clinical impact.

A. Serretti, S. Kasper, J. Mendlewicz, 2019, International clinical psychopharmacology.

Are higher doses more effective in OCD?

N. Fineberg, S. Montgomery, A. Roberts, 1994, European Neuropsychopharmacology.

Serotonin reuptake inhibitors are the treatment of choice in obsessive compulsive disorder

N. Fineberg, S. Montgomery, D. Montgomery, 1992, International clinical psychopharmacology.

Dimensions of Delusions in Major Depression: Socio-demographic and Clinical Correlates in an Unipolar-Bipolar Sample

A. Serretti, S. Kasper, J. Mendlewicz, 2015, Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology.

Treatment resistant depression: methodological overview and operational criteria

J. Amsterdam, C. Montigny, Y. Lecrubier, 1999, European Neuropsychopharmacology.

The place of obsessive compulsive disorder in the diagnostic hierarchy

S. Montgomery, 1992, International Clinical Psychopharmacology.

Selecting the optimum therapeutic dose of serotonin reuptake inhibitors: studies with citalopram

S. Montgomery, 1995, International clinical psychopharmacology.

Mianserin plasma levels and differential clinical response in endogenous and reactive depression.

S. Montgomery, R. McAuley, D. Montgomery, 1978, Acta psychiatrica Belgica.

An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram

S. Montgomery, C. DeVane, H. Liston, 2000, International clinical psychopharmacology.

A Randomised Study Comparing Escitalopram with Venlafaxine XR in Primary Care Patients with Major Depressive Disorder

S. Montgomery, J. Bothmer, S. Montgomery, 2004, Neuropsychobiology.

Clinically relevant effect sizes in depression

S. Montgomery, 1994, European Neuropsychopharmacology.

[Biological treatments in obsessive-compulsive disorder].

N. Fineberg, S. Montgomery, D. Montgomery, 1990, L'Encephale.

Focus on social functioning in depression.

M. Keller, R. Hirschfeld, S. Kasper, 1998, International journal of psychiatry in clinical practice.

Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study

S. Kennedy, I. Hindmarch, S. Montgomery, 2004, International clinical psychopharmacology.

A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder

A. McIntyre, J. Zohar, S. Montgomery, 1993, European Neuropsychopharmacology.

The Role of Relationship Status in Major Depressive Disorder - Results of the European Group for the Study of Resistant Depression.

A. Serretti, L. Mandelli, L. Bartova, 2021, Journal of affective disorders.

The role of noradrenaline and selective noradrenaline reuptake inhibition in depression

E. Paykel, S. Kasper, J. Mendlewicz, 2002, European Neuropsychopharmacology.

Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: a pooled survival analysis of 7 double-blind, randomized clinical trials.

M. Thase, S. Montgomery, A. Krishen, 2007, The Journal of clinical psychiatry.

Dose Response Relationship of Citalopram 20 mg, Citalopram 40 mg and Placebo in the Treatment of Moderate and Severe Depression

S. Montgomery, K. Lyby, J. Rasmussen, 1992 .

Citalopram 20 mg, citalopram 40 mg and placebo in the prevention of relapse of major depression.

S. Montgomery, J. Rasmussen, 1992 .

Supersensitivity and nomifensine in depressed patients.

S. Montgomery, D. Montgomery, D. Roy, 1982, Advances in biochemical psychopharmacology.

Evaluation of MADRS severity thresholds in patients with bipolar depression.

J. Calabrese, M. Thase, S. Montgomery, 2021, Journal of affective disorders.

New antidepressants and 5‐HT uptake inhibitors

S. Montgomery, S. Montgomery, 1989, Acta psychiatrica Scandinavica. Supplementum.

Profiles of antidepressant activity with the Montgomery‐Asberg depression rating scale

S. Montgomery, N. Smeyatsky, D. Montgomery, 1985, Acta psychiatrica Scandinavica. Supplementum.

Age, depression and tricyclic antidepressant levels

R. Braithwaite, S. Montgomery, S. Dawling, 1979 .

Mixed, melancholic, and anxious features in depression: a cross-sectional study of sociodemographic and clinical correlates.

A. Serretti, S. Kasper, J. Mendlewicz, 2014, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

Switching Antidepressant Class Does Not Improve Response or Remission in Treatment-Resistant Depression

A. Serretti, Y. Lecrubier, S. Kasper, 2011, Journal of clinical psychopharmacology.

Social phobia: diagnosis, severity and implications for treatment

S. Montgomery, 1999, European Archives of Psychiatry and Clinical Neuroscience.

Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo

G. Dunbar, D. Dunner, S. Montgomery, 1995, European Neuropsychopharmacology.

Is There a Role for Switching Antidepressants in Treatment‐resistant Depression?

S. Montgomery, 2013 .

Antidepressant therapy in the chronic fatigue syndrome.

S. Montgomery, S. Lynch, R. Seth, 1991, The British journal of general practice : the journal of the Royal College of General Practitioners.

Improving the chance of recovery from the short‐ and long‐term consequences of depression

H. Möller, K. Demyttenaere, S. Montgomery, 2003, International clinical psychopharmacology.

Economic considerations in the prescribing of third-generation antidepressants

J. Doyle, S. Montgomery, L. Stern, 2012, PharmacoEconomics.

Do some antidepressants promote suicide?

S. Montgomery, R. Pinder, 2004, Psychopharmacology.

The risk of suicide with antidepressants.

S. Montgomery, M. Lambert, S. Lynch, 1988, International clinical psychopharmacology.

Citalopram 20 mg, citalopram 40 mg and placebo in the prevention of relapse of major depression

S. Montgomery, J. Rasmussen, 1992, European Neuropsychopharmacology.